Hexarelin vs Ipamorelin

Side-by-side comparison of Hexarelin, Ipamorelin — mechanism, dosing, half-life, side effects, and research status.

← Pick different peptides
Attribute Hexarelin Hexarelin (Examorelin) Growth Hormone Ipamorelin Ipamorelin (Selective GHRP) Growth Hormone
Basics
Molecular type Growth Hormone Releasing Peptide (GHRP)Growth Hormone Releasing Peptide (GHRP)
Amino acids 65
Molecular weight 887.1 Da711.9 Da
Half-life ~2 hours~2 hours
Route(s) Subcutaneous, Intramuscular, IntranasalSubcutaneous, Intramuscular
Mechanism & Research
Primary mechanism Hexarelin activates GHSR-1a with exceptionally high potency, producing GH pulse amplitudes that exceed GHRP-2 and GHRP-6 at equivalent doses. It also acts at the hypothalamic level to suppress somatostatin, contributing … Ipamorelin activates growth hormone secretagogue receptors (GHSR-1a) in the pituitary, triggering pulsatile GH release. Unlike first-generation GHRPs (GHRP-6, GHRP-2), ipamorelin's selectivity for GHSR-1a is high enough …
Research status Research Compound Research Compound
Evidence summary Hexarelin has Phase 1/2 clinical data including cardiac research. Its direct cardioprotective mechanism is one of the most distinctive features of any GHRP. Research also supports its use in GH deficiency testing. Ipamorelin was among the first highly selective GHRPs to enter research. Phase 1 trials confirmed its clean hormonal profile. It remains a reference GHRP in comparative studies and is widely used as the GHRP component in…
Protocol & Dosing
Typical dose 100–200 mcg per injection100–300 mcg per injection
Frequency 2× daily2–3x daily (or 1x at bedtime)
Duration 4–6 weeks maximum (desensitisation concern)8–12 weeks on, 4 weeks off
Timing Fasted stateFasted state or 2+ hours post-meal for maximum GH response; bedtime dosing utilises natural nocturnal GH pulse
Safety
Common side effects
  • Cortisol elevation (significant at higher doses)
  • Prolactin increase
  • Rapid receptor desensitisation
  • Water retention
  • Water retention (mild)
  • Tingling/numbness (extremities)
  • Headache (transient)
  • Injection site redness
Contraindications
  • Active malignancy
  • Cardiac conditions (paradoxical concern despite cardiac data — consult cardiologist)
  • Pregnancy
  • Active malignancy
  • Uncontrolled diabetes
  • Pregnancy
Anti-doping Prohibited (WADA S2) Prohibited (WADA S2)
Deeper reading
Related peptides GHRP-2, GHRP-6, Ipamorelin CJC-1295, GHRP-2, Sermorelin, Tesamorelin
Full profile Read full Hexarelin profile → Read full Ipamorelin profile →

Comparison data is compiled from each peptide’s individual profile. All values are drawn from peer-reviewed research and regulatory sources. For educational use only — not medical advice. Verify any protocol with a qualified healthcare provider.